Meril Life Sciences' LANDMARK trial, highlighting the safety and effectiveness of the Myval Transcatheter Heart Valve Series, stands out as a key late-breaking trial at EuroPCR 2024
Bristol Myers Squibb announced the FDA has granted accelerated approval for Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received two or more prior lines of systemic therapy
89bio, Inc. announced the initiation of ENLIGHTEN-Cirrhosis, a Phase III trial of pegozafermin in patients with MASH with compensated cirrhosis (F4)